Aastrom Biosciences to Present at Merriman Curhan Ford & Co. 3rd Annual Investor Summit

ANN ARBOR, Mich., Sept. 14  /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) today announced that George W. Dunbar, President and Chief Executive Officer, Gerald D. Brennan, Jr., Vice President Administrative & Financial Operations and Chief Financial Officer, and Elmar R. Burchardt, M.D., Ph.D., Vice President Medical Affairs will present at the Merriman Curhan Ford & Co. 3rd Annual Investor Summit.  The conference will be held September 18-20th at The Mark Hopkins InterContinental Hotel in San Francisco, CA.  Aastrom will present on Monday, September 18th at 10:15 a.m. (Pacific Time) or 1:15 p.m. (Eastern Time).

(Logo:  http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO )

A live webcast of Aastrom's presentation can be accessed by logging onto the web at http://www.wsw.com/webcast/mcm4/astm/.  A replay of the presentation will be archived through September 20th at the same site.  For more information about the Merriman Curhan Ford & Co. conference, please visit http://www.merrimanco.com/.

About Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products are a unique cell mixture containing stromal, stem and progenitor cell populations, produced outside the body from a small amount of bone marrow taken from the patient. TRC-based products have been used in over 225 patients, and are currently in clinical trials for bone regeneration (long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications. The Company has reported positive interim clinical trial results for TRCs suggesting both the clinical safety and the ability of TRCs to induce tissue regeneration in long bone fractures and jaw bone reconstruction. Recently, the Company's proprietary TRCs received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of osteonecrosis of the femoral head. In addition, Aastrom is developing plans for a TRC-based therapy for cardiac regeneration.

For more information, visit Aastrom's website at http://www.aastrom.com/ .

This document contains forward-looking statements, including without limitation, statements regarding product development objectives, market development plans, and potential advantages and applications of Tissue Repair Cells, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "plans," and other words of similar meaning.  Actual results may differ significantly from the expectations contained in the forward-looking statements.  Among the factors that may result in differences are the results obtained from clinical trial activities, regulatory approval requirements, and the availability of resources.  These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACTS:  Kris M. Maly                    Cameron Associates
           Investor Relations Department   Kevin McGrath
           Aastrom Biosciences, Inc.       Phone:  [phone]
           Phone:  [phone]          Deanne Eagle (Media)
                                           Phone: [phone]


http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO

http://photoarchive.ap.org/

DATASOURCE: Aastrom Biosciences, Inc.



CONTACT:  Kris M. Maly, Investor Relations Department of Aastrom

Biosciences, Inc., [phone]; or Kevin McGrath, [phone], or

Deanne Eagle (Media), [phone], both of Cameron Associates



Web site:  http://www.aastrom.com/ 

Copyright